Chronic Myeloid Leukaemia

Note: The information on cancer types on the ACRF website is not designed to provide medical or professional advice and is for information only. If you have any health problems or questions please consult your doctor.

  • What is Chronic Myeloid Leukaemia (CML)?

    Commonly, Chronic Myeloid Leukaemia (CML – also called chronic myelogenous leukaemia) is caused by a genetic abnormality in the blood cells, called the Philadelphia (Ph) chromosome. It is a mutation in the DNA that causes the bone marrow to make an enzyme called tyrosine kinase, which in turn causes too many stem cells to become white blood cells.

    In particular, chronic myeloid leukaemia affects white blood cells called myloblasts. These leukaemic white blood cells gradually crowd the bone marrow, disrupting normal blood cell production. They also spill out of the bone marrow and circulate around the body via the bloodstream.

  • Chronic myeloid leukaemia symptoms

    As with other types of Leukaemia, the white blood cells aren’t fully developed and are therefore unable to fight infections. Meanwhile, the disease causes a shortage of red blood cells and platelets. Patients will therefore experience symptoms of anaemia, bleeding and/or bruising.

    Usually, CML develops gradually. It is often diagnosed according to three different stages of progression: the chronic phase, the accelerated phase, and the blast phase. These stages are defined by the number of immature white blood cells in the blood and bone marrow, as well as the intensity of symptoms. CML is known to change into a fast-growing acute leukaemia.

    Because CML is typically slow to develop, it can be present for a number of years before it is detected. CML is diagnosed by a full blood count (FBC) and a bone marrow biopsy/examination.

  • Chronic myeloid leukaemia treatment

    Depending on the phase of the disease, general health of the patient and their age, different treatment schedules will apply. During the chronic phase, which is generally low-risk, treatment is designed to control the progression of CML and keep blood counts with a relatively normal range. The treatment can usually be taken at home, via an oral chemotherapy tablet.

    Treatment may also involve a type of tyrosine kinase inhibitor (to prevent the function of the mutated ph- chromosome).

    For patients with accelerated chronic myeloid leukaemia, the disease has progressed more quickly and symptoms have started to develop. In the blast phase, the situation is again higher-risk.

    Depending on the severity of the disease, patients will undergo a combination of chemotherapy drugs given intravenously. This treatment is designed to eliminate the leukaemic blood cells, bringing blood levels back to the chronic stage of the disease.

    Sometimes, in cases with significantly high levels of leukaemic cells in their blood, a process called ‘leukopheresis’ might be used. Similar to dialysis, this process removes the cells from the blood by passing it through a special machine, before the blood is passed back into the body.

Chronic myeloid leukaemia statistics

  • 391

    new cases are estimated to be diagnosed in 2022

  • 61.4

    is the median age of CML diagnosis

  • 83.4%

    is the estimated five-year survival rate for CML in Australia

Help to change the statistics by
backing brilliant cancer research.


Cancer in Australia 2017, Australian Institute of Health and Welfare

Latest Cancer Research Updates